Oxford BioMedica is a world leading gene and cell therapy company focused on developing life changing treatments for serious diseases. They have built a platform of exclusive cutting-edge technologies and capabilities, based on a sector leading and proprietary single dose gene therapy platform (LentiVector®), with which they design, develop and produce gene and cell based medicines for themselves and for their partners.
Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells and has thein vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body.
Through their LentiVector® delivery platform Oxford BioMedica have created a valuable and focused portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. They have a broader interest in multiple partnered royalty-bearing product candidates with Novartis, Sanofi and Immune Design, among others.